• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CanSAR cancer database to use artificial intelligence to discover cancer treatments

CanSAR cancer database to use artificial intelligence to discover cancer treatments

November 15, 2013
CenterWatch Staff

A new cancer database containing 1.7 billion experimental results will utilize artificial intelligence—similar to the technology used to predict the weather—to discover the cancer treatments of the future.

The system, called CanSAR, is the biggest disease database of its kind anywhere in the world and condenses more data than would be generated by one million years of use of the Hubble space telescope.

It has been developed by researchers at The Institute of Cancer Research, London, using funding from Cancer Research U.K.

The new CanSAR database is more than double the size of a previous version and has been designed to cope with a huge expansion of data on cancer brought about by advances in DNA sequencing and other technologies.

The resource is being made freely available by The Institute of Cancer Research (ICR) and Cancer Research U.K., and will help researchers worldwide make use of vast quantities of data, including data from patients, clinical trials and genetic, biochemical and pharmacological research.

Although the prototype of CanSAR was on a much smaller scale, it attracted 26,000 unique users in more than 70 countries around the world and earlier this year was used to identify 46 potentially “druggable” cancer proteins that previously had been overlooked.

The new database will drive further dramatic advances in drug discovery by allowing researchers access to, and the ability to interact with, unprecedented amounts of multidisciplinary data in seconds.

CanSAR now contains more than eight million experimentally derived measurements, nearly one million biologically active chemical compounds and data from over one thousand cancer cell lines. It also contains drug target information from the human genome and model organisms. Research that previously had taken months to complete now will take only minutes.

Dr. Bissan Al-Lazikani, team leader in computational biology and chemogenomics at the ICR, said, “CanSAR uses artificial intelligence, like that used in weather forecasts, to predict which potential drugs are likely to work in which circumstances. The database is capable of extraordinarily complex virtual experiments drawing on information from patients, genetics, chemistry and other laboratory research. It can spot opportunities for future cancer treatments that no human eye could be expected to see.”

Nell Barrie, Cancer Research U.K.’s senior science information manager, said, “Research into cancer relies on international collaboration, and the CanSAR database makes it easy for scientists around the world to tap into huge amounts of information—from the lab and the clinic—to fuel new discoveries. The clues we need to tackle cancer are hidden in data like this, and by making it freely available we can boost our progress and make breakthroughs sooner.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing